Targets › FXN
5 programs from 4 companies in 6 trials: 3 Phase 1, 2 Phase 2, 1 Phase 3; Neurology, Cardiovascular; next expected readout Jan 2027.
[Frataxin mature form]: Functions as an activator of persulfide transfer to the scaffoding protein ISCU as component of the core iron-sulfur cluster (ISC) assembly complex and participates to the [2Fe-2S] cluster assembly. Accelerates sulfur transfer from NFS1 persulfide intermediate to ISCU and to small thiols such as L-cysteine and glutathione leading to persulfuration of these thiols and ultimately sulfide…. (UniProt, Q16595)
Open in Phaseline: the race on FXN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Larimar Therapeutics | Nomlabofusp Recombinant human frataxin fusion protein | FXN | Phase 3 | Friedreich Ataxia | Jul 2029 |
| Larimar Therapeutics | CTI-1601 Recombinant fusion protein delivering human frataxin | FXN | Phase 2 | Friedreich Ataxia | Jan 2027 |
| Lexeo Therapeutics | LX2006 Adeno-associated viral vector (AAVrh.10) delivering the human frataxin (FXN) gene to cardi | FXN | Phase 2 | Friedreich Ataxia | Sep 2029 |
| Solid Biosciences | SGT-212 Adeno-associated virus serotype AAVhu68 containing codon-optimized complementary DNA for F | FXN | Phase 1 | Friedreich's Ataxia (FA) | Mar 2028 |
| Weill Medical College of Cornell University | AAVrh.10hFXN Adeno-associated virus serotype rh.10 gene transfer vector expressing human frataxin (FXN) | FXN | Phase 1 | Friedreich Ataxia | Dec 2028 |
Friedreich Ataxia (5) Friedreich's Ataxia (FA) (1)
small molecule (3), mixed (1), other (1)
Larimar Therapeutics (2) Weill Medical College of Cornell University (1) Lexeo Therapeutics (1) Solid Biosciences (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.